Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Patients With Type 2 Diabetes
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes
Diabetes Care 2023 Nov 01;46(11)2004-2014, A Kutz, DH Kim, DJ Wexler, J Liu, S Schneeweiss, RJ Glynn, E PatornoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.